Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Kenneth Cusi
Hepatology (2019) Vol. 69, Iss. 6, pp. 2318-2322
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 12, pp. 1113-1124
Open Access | Times Cited: 1299
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 366
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 348
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 246
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 145
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 144
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 116
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Xunzhe Yin, Xiangyu Guo, Zuojia Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2844-2844
Open Access | Times Cited: 46
The future of liver transplantation
Sandy Feng, Garrett R. Roll, Foad J. Rouhani, et al.
Hepatology (2024)
Closed Access | Times Cited: 15
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
Qiuyu Xu, Jie Zhang, Yan Lü, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108783-108783
Open Access | Times Cited: 11
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Kenneth Cusi
Diabetes Care (2020) Vol. 43, Iss. 2, pp. 275-279
Open Access | Times Cited: 56
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Jeffrey Budd, Kenneth Cusi
The American Journal of Medicine (2020) Vol. 133, Iss. 5, pp. 536-543
Closed Access | Times Cited: 52
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Jeffrey Budd, Kenneth Cusi
Current Diabetes Reports (2020) Vol. 20, Iss. 11
Closed Access | Times Cited: 51
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
Nicholas Chew, Cheng Han Ng, Mark Muthiah, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 515-532
Closed Access | Times Cited: 32
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
Kenneth Cusi
Liver International (2020) Vol. 40, Iss. S1, pp. 82-88
Open Access | Times Cited: 44
Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Qian Luo, Ruojun Wei, Yuzi Cai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 22
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
Yearbook of pediatric endocrinology (2021)
Open Access | Times Cited: 30
Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest
Rafael García Carretero, Roberto Holgado–Cuadrado, Óscar Barquero‐Pérez
Entropy (2021) Vol. 23, Iss. 6, pp. 763-763
Open Access | Times Cited: 24
Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database
Tingxi Wu, Yang Zhang, Yanfeng Shi, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 11, pp. 965-975
Closed Access | Times Cited: 17
Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia
Juan M. Munoz Pena, Kenneth Cusi
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 1, pp. e1-e11
Open Access | Times Cited: 9
Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
Lucia Brodosi, Salvatore Petta, Maria Letizia Petroni, et al.
Transplantation (2021) Vol. 106, Iss. 3, pp. 462-478
Open Access | Times Cited: 21
The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis
Hou Wang, Lingling Wang, Yun Li, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 140, pp. 111778-111778
Open Access | Times Cited: 19
Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway
Jie Yu, Yuan Zhao, Lingling Xu, et al.
Mediators of Inflammation (2023) Vol. 2023, pp. 1-12
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top